Nanobiotix, a former NCL collaborator and Assay Cascade awardee, recently announced positive results from a phase 2/3 study of NBTXR3 in soft tissue sarcoma. NBTXR3 (hafnium oxide nanoparticles) combined with radiotherapy showed a better response than radiotherapy alone in a trial of 180 patients. From the Nanobiotix website:
- Trial achieved its primary endpoint of pathological Complete Response Rate
- Trial achieved its secondary endpoint in operability (R0 rate)
- NBTXR3 demonstrated significant superiority and clinical benefits for patients versus standard of care
- Safety profile confirmed
- Randomized trial validated the first-in-class mode of action of NBTXR3
Read the full press release from Nanobiotix.